



PARADIGM TO HOST CONFERENCE CALL TO PRESENT RESULTS FROM PHASE 2B CLINICAL TRIAL OF iPPS IN KNEE OSTEOARTHRITIS PAIN

Melbourne 17 December 2018, Paradigm Biopharmaceuticals Ltd (ASX: PAR): Paradigm is pleased to announce that it will host a conference call at 9:00am (AEDT) Tuesday 18th December 2018 to present and discuss the results from the Phase 2b, randomised double blind placebo controlled multicentre study. The clinical trial was conducted to evaluate the effects of injectable Pentosan Polysulfate sodium (iPPS) on the treatment of pain in subjects with osteoarthritis of the knee and concurrent subchondral bone marrow edema lesions.

Phase 2b OA/BMEL Results Teleconference Details

You are invited to participate in a conference call held by Mr. Paul Rennie (CEO), Prof. Andrew Östör (Principle Investigator), Dr. Ravi Krishnan (CSO) & Dr. Claire Kaufman (COO).

The call is scheduled for 9:00am (AEDT) Tuesday 18th December (US PST 2:00pm / EST 5:00pm on Monday 17th; UK 5:00am on Tuesday 18th).

Conference ID - 221766

Dial-in Details

Diamond Pass Registration Link

In order to pre-register for this conference and avoid a queue when calling, please follow the link below. You will be given a unique pin number to enter when you call which will bypass the operator and give you immediate access to the event.

<https://services.choruscall.com.au/diamondpass/paradigmbiopharma-221766-invite.html>

If you are unable to register, then at the time of the conference you can call one of the numbers below and provide the **Conference ID 221766** to an operator

Australia Toll Free:	1800 908 299	Australia Alt. Toll Free:	1800 455 963
Australia Local:	+61 2 9007 8048	Australia Alt. Local:	+61 7 3145 4005
New Zealand Toll Free:	0800 452 795	Auckland Local:	+64 9 929 3905
Germany Toll Free:	0800 183 0918	China Toll Free:	1080 0140 1776
USA/Canada Toll Free:	1855 624 0077	France Toll Free:	0800 913 734
Hong Kong Toll Free:	800 968 273	UAE Toll Free:	8000 3570 2706
UK Toll Free:	0800 051 1453	Switzerland Toll Free:	0800 802 498
Singapore Toll Free:	800 101 2702	India Toll Free:	000 800 100 8070
Japan Toll Free:	0066 3386 8000	Indonesia Toll Free:	007 803 321 8057

For personal use only

Q&A Instructions

In order to ask a question during the Live Question and Answer Session:

Press * then 1 on your telephone keypad to enter the Q&A queue

Press * then 2 on your telephone keypad to withdraw your question

ABOUT PARADIGM BIOPHARMACEUTICALS LTD

Paradigm Biopharmaceuticals Limited (ASX: PAR) is an ASX-listed biotechnology company focused on repurposing Pentosan Polysulfate Sodium (PPS), an FDA approved drug that has a long track record of safely treating inflammation over 60 years.

On 18 December 2018 the Company will announce the results of a phase 2b randomised, double blind, placebo controlled multicentre trial, investigating subjects with osteoarthritis and concurrent bone marrow edema lesions. The recruitment of the 110 subjects into the clinical trial commenced in November 2017 and concluded in August 2018. There is a global trend for safe and effective non-opioid and non-steroid pain relief for chronic disease such as osteoarthritis which presents a huge market opportunity for Paradigm's PPS treatment.

Subject to successful phase 2b results, the Company is aiming to achieve Fast-Track designation and begin conducting a phase 3 trial in the US in CY2019. Successful phase 2b trials and Fast-Track designation would be expected to generate significant big pharma interest.

In July 2017 the Company commenced a phase 2a clinical trial to treat people recently infected with the Ross River virus. The results of this trial are also expected to be released in Q1CY2019.

Paradigm recently executed an Exclusive In-License Agreement for the use of iPPS in the treatment of mucopolysaccharidoses (MPS), a group of inherited lysosomal storage disorders. A key unmet medical need in this class of inherited disease is the lack of treatment of joint pain and dysfunction akin to osteoarthritis, hence the applicability of iPPS in treating these rare joint diseases.

The Company continues to execute on its drug repurposing strategy. The key benefits of this strategy are lower costs, accelerated development timelines and higher success rates than the standard clinical development timeline.

To learn more please visit: www.paradigmbiopharma.com

For more information, please contact

Investor Enquiries

Dirk van Dissel
Adelaide Equity Partners
E: dvandissel@adelaideequity.com.au
M: +61 408 326 367

Alastair Murray
Adelaide Equity Partners
E: amurray@adelaideequity.com.au
M: +61 415 629 977

For personal use only